Company intelligence / Profile preview

OcuTerra Therapeutics

Boston, Massachusetts, United Statesocuterratx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

OcuTerra's lead candidate nesvategrast (OTT166 5%) completed Phase 2 clinical trials (DR:EAM study) in March 2024. The drug met its primary safety endpoint but failed to meet primary and secondary efficacy endpoints for treating diabetic retinopathy. The company is reviewing the full dataset to evaluate the future of the program.

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

nesvategrast

Beyond the preview

Go deeper on OcuTerra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OcuTerra Therapeutics.

Explore the full profile